| Autor: |
Rodriguez L; Pulmonary, Allergy, and Critical Care Medicine Division and., Tomer Y; Pulmonary, Allergy, and Critical Care Medicine Division and., Carson P; Pulmonary, Allergy, and Critical Care Medicine Division and., Dimopoulos T; Pulmonary, Allergy, and Critical Care Medicine Division and., Zhao M; Pulmonary, Allergy, and Critical Care Medicine Division and., Chavez K; Pulmonary, Allergy, and Critical Care Medicine Division and., Iyer S; Pulmonary, Allergy, and Critical Care Medicine Division and., Huang L; Fibrosis Biology Drug Discovery, Bristol-Myers Squibb, Lawrenceville, New Jersey; and., Ebert C; Fibrosis Biology Drug Discovery, Bristol-Myers Squibb, Lawrenceville, New Jersey; and., Sereda L; Fibrosis Biology Drug Discovery, Bristol-Myers Squibb, Lawrenceville, New Jersey; and., Murthy A; Pulmonary, Allergy, and Critical Care Medicine Division and., Trujillo G; Fibrosis Biology Drug Discovery, Bristol-Myers Squibb, Lawrenceville, New Jersey; and., Beers MF; Pulmonary, Allergy, and Critical Care Medicine Division and.; PENN-CHOP Lung Biology Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.; The Michael Crescenz VA Medical Center, Philadelphia, Pennsylvania., Katzen J; Pulmonary, Allergy, and Critical Care Medicine Division and.; PENN-CHOP Lung Biology Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. |
| Abstrakt: |
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic interstitial lung disease. A barrier to developing more effective therapies for IPF is the dearth of preclinical models that recapitulate the early pathobiology of this disease. Intratracheal bleomycin, the conventional preclinical murine model of IPF, fails to reproduce the intrinsic dysfunction to the alveolar epithelial type 2 cell (AEC2) that is believed to be a proximal event in the pathogenesis of IPF. Murine fibrosis models based on SFTPC (Surfactant Protein C gene) mutations identified in patients with interstitial lung disease cause activation of the AEC2 unfolded protein response and endoplasmic reticulum stress-an AEC2 dysfunction phenotype observed in IPF. Although these models achieve spontaneous fibrosis, they do so with precedent lung injury and thus are challenged to phenocopy the general clinical course of patients with IPF-gradual progressive fibrosis and loss of lung function. Here, we report a refinement of a murine Sftpc mutation model to recapitulate the clinical course, physiological impairment, parenchymal cellular composition, and biomarkers associated with IPF. This platform provides the field with an innovative model to understand IPF pathogenesis and index preclinical therapeutic candidates. |
